SOURCE: Lpath, Inc.

February 13, 2009 13:09 ET

Lpath to Present at the ROTH Capital Partners 21st Annual Growth Stock Conference

SAN DIEGO, CA--(Marketwire - February 13, 2009) - Lpath, Inc. (OTCBB: LPTN) plans to present at the 21st Annual ROTH Capital Partners Growth Stock Conference, which will be held February 16-18, 2009 at the Ritz Carlton Laguna Niguel in Dana Point, California.

The ROTH Capital Partners Growth Stock Conference is one of the largest in the nation for micro-cap and small-cap companies in technology, healthcare, financial services, and consumer products sectors. More than 1,000 institutional investors are expected to attend.

Lpath President and CEO Scott R. Pancoast is scheduled to present on Monday, February 16 at 1:20 PM Pacific Time (4:20 PM Eastern Time), followed by a breakout session and one-on-one meetings. The presentation will be available via webcast at

For more information on the ROTH conference, please visit the conference website at For media inquiries and press credentials call 949-720-5700.

About ROTH Capital Partners, LLC:

With corporate headquarters in Newport Beach, California, ROTH is a full-service investment banking firm dedicated to the small and micro-cap markets. The firm is privately owned with current principals being majority owners, and the core management team has been consistent for many years. Since the inception of the firm in 1984, ROTH has been a leader and innovator in the small and micro-cap markets. ROTH's exclusive focus has been, is currently, and will continue to be the offering of a full spectrum of investment banking services, including raising capital, research coverage, trading and market making, merger and acquisition advisory services, and investor conferences. It is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Please visit

About Lpath:

Lpath, Inc., headquartered in San Diego, is the category leader in bioactive-lipid-targeted therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP™, an antibody against Sphingosine-1-Phosphate (S1P), is currently in a Phase 1 clinical trial in cancer and also holds promise against multiple sclerosis and various other disorders. ASONEP is being developed with the support of partner Merck-Serono as part of a worldwide exclusive license. A second product candidate, iSONEP™ (the ocular formulation of the S1P antibody), has demonstrated superior results in various preclinical models of age-related macular degeneration (AMD) and retinopathy and is in a Phase 1 clinical trial in wet-AMD patients. Lpath's third product candidate, Lpathomab™, is an antibody against Lysophosphatidic Acid (LPA), a key bioactive lipid that has been long recognized as a valid disease target (cancer, neuropathic pain, fibrosis). The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2™ drug-discovery engine, which the company is leveraging as a means to expand its pipeline. Please visit

Contact Information